FDA Tobacco Committee Meets: Comments Sought
Published Date: 11/24/2025
Notice
Summary
The FDA is hosting a public online meeting on January 22, 2026, where experts will discuss tobacco product rules and give advice. Anyone interested can share their thoughts by January 21, 2026, through a public comment system. This meeting affects tobacco companies, public health groups, and anyone curious about tobacco safety and regulations.
Analyzed Economic Effects
5 provisions identified: 4 benefits, 0 costs, 1 mixed.
TPSAC will review ZYN MRTP applications
On January 22, 2026, the Committee will discuss modified risk tobacco product applications submitted by Swedish Match USA, Inc. for a list of ZYN products (including Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth/Original, Chill/Classic, Menthol/Fresh in 3 mg and 6 mg variants). Discussion will focus on relative health risks, consumer understanding of proposed claims, and potential public health impact of a modified risk marketing order.
Public comment docket and deadlines
The FDA opened docket FDA-2025-N-0835 for public comments on the Tobacco Products Scientific Advisory Committee meeting. Electronic comments are accepted until 11:59 p.m. ET on January 21, 2026; comments received on or before January 7, 2026 will be provided to the Committee, while comments received after January 7, 2026 will be considered by FDA but not provided to the Committee.
Opportunity to give oral testimony
People who want to speak at the advisory committee must request to speak and submit a brief statement with names and contact information by 12:00 p.m. ET on December 31, 2025. Oral presentations are scheduled between about 1:00 p.m. and 2:00 p.m. ET on January 22, 2026, and FDA may run a lottery if there are more registrants than can be accommodated.
Meeting available online and captioned
The TPSAC meeting on January 22, 2026 (9:00 a.m. to 4:30 p.m. ET) will be held via an online video conferencing platform, will be captioned and recorded, and will be available at the provided YouTube live link on the day of the meeting. FDA intends to post background material no later than 2 business days before the meeting, and if not posted beforehand, will make materials available at the time of the meeting and post them after the meeting.
Disability accommodations request window
FDA will make efforts to accommodate persons with disabilities at the advisory committee meeting; if you require accommodations, you must contact the designated FDA official at least 7 days before the meeting.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-13047 — Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-13101 — Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock Absorber
The FDA is officially classifying the medial knee implanted shock absorber as a Class II device, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps patients get access to this innovative knee device faster and with confidence in its safety. The new classification is effective June 29, 2026, and could save time and money for makers and users alike.
2026-13005 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; New Animal Drugs for Minor Use and Minor Species
The FDA is asking for public feedback on their plan to keep collecting info about new animal drugs for rare uses and less common species. This affects drug makers who want special approval and incentives for these unique animal medicines. Comments are open until July 29, 2026, and the process helps keep these important drugs safe and available without extra costs.
2026-13006 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYALEV
The FDA has officially set the review period for the drug VYALEV, which helps the company extend its patent protection. This means the patent clock can be paused, giving the drug maker more time to sell VYALEV exclusively. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by late 2026.
2026-12906 — Revocation of Three Authorizations of Emergency Use of In Vitro Diagnostic Devices for Detection and/or Diagnosis of COVID-19; Availability
The FDA has officially ended emergency use for three COVID-19 test kits from BD, InBios, and Roche as of early 2026. This means these specific tests are no longer authorized for quick COVID-19 detection or diagnosis. If you or your organization used these tests, it’s time to switch to other approved options—no extra costs or penalties, just a smooth transition.
2026-12884 — Agency Information Collection Activities; Proposed Collection; Comment Request; Time and Extent Applications for Nonprescription Drug Products
The FDA wants your thoughts on how they collect info about nonprescription drug applications, especially about timing and usage. This affects drug makers and anyone interested in over-the-counter meds. You’ve got until August 25, 2026, to share your comments—no fees, just your voice helping shape the process!
Previous / Next Documents
Previous: 2025-20767 — Intercept Pharmaceuticals, Inc., et al.; Withdrawal of Approval of New Drug Application for OCALIVA (Obeticholic Acid) Tablets, 5 Milligrams and 10 Milligrams, and Three Abbreviated New Drug Applications for Obeticholic Acid Tablets, 5 Milligrams and 10 Milligrams
The FDA is officially pulling the approval for OCALIVA tablets (5 mg and 10 mg) and similar versions from three other companies, effective November 24, 2025. This affects patients, doctors, and pharmacies who use or sell these drugs, meaning they’ll need to find alternatives soon. The companies themselves asked for this change, so no surprise fees or penalties are involved.
Next: 2025-20769 — Request for Information for 2027 Department of Defense (DoD) State Policy Priorities Impacting Service Members and Their Families
The Department of Defense is asking for ideas to help states make life easier for military members and their families in 2027. They want to fix problems like school changes for kids and retirement benefits for military spouses. This effort could lead to new state policies that save money and reduce stress for military families starting soon.